It reduces inflammation in myocardial fibrosis by inhibiting some signaling pathways, such as MAPKs (196), phosphatidyl-inositol 3-kinase (PI3K) (197), TGF-β (198), and NF-κB (199), and reducing MMP-9 and MMP-2 (200). The gene discussed is TGFB1; the disease is Myocardial fibrosis.